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Abstract
Ovarian cancer patients treated with cisplatin-based chemotherapy often develop acquired cisplatin resistance
and, consequently, cancer recurrence. We have previously reported that annexin A11 is associated with cisplatin
resistance and related to tumor recurrence in ovarian cancer patients. In this study, we used small interfering RNA
to suppress annexin A11 expression in ovarian cancer cells followed by various in vitro assays. We showed that
knockdown of annexin A11 expression reduced cell proliferation and colony formation ability of ovarian cancer
cells. Epigenetic silencing of annexin A11 conferred cisplatin resistance to ovarian cancer cells. Through a com-
prehensive time course study of cisplatin response in ovarian cancer cells with/without suppression of annexin
A11 expression using whole-genome oligonucleotide microarrays, we identified a set of differentially expressed
genes associated with annexin A11 expression and some patterns of gene expressions in response to cisplatin
exposure. These identified genes/patterns were further validated by real-time polymerase chain reaction and im-
munoblot analysis. Many of them such as HMOX1, TGFBI, LY6D, S100P, EIF4EBP2, DHRS2, and PCSK9 have
been involved in apoptosis, cell cycling/proliferation, cell adhesion/migration, transcription regulation, and signal
transduction. In addition, immunohistochemistry analyses indicated that annexin A11 immunointensity inversely cor-
related with HMOX1 immunoreactivity in 142 ovarian cancer patients. In contrast to annexin A11, HMOX1 immuno-
reactivity positively correlated with in vitro cisplatin resistance in ovarian cancers. Collectively, annexin A11 is directly
involved in cell proliferation and cisplatin resistance of ovarian cancer. Manipulation of annexin A11 and its associated
genes may represent a novel therapeutic strategy in human ovarian cancers.
Neoplasia (2009) 11, 605–614
Introduction
Ovarian cancer is the fifth leading cause of cancer death among U.S.
women and has the highest mortality rate of all gynecologic cancers
[1]. Up to 80% of patients whose conditions have been diagnosed at
advanced stages of ovarian cancer die within 5 years [1,2]. Many of
them, after undergoing debulking surgery, initially respond to chemo-
therapy yet later relapse with recurrent tumors that are refractory to
the original treatment, eventually succumbing to the disease [3,4]. Ac-
quisition of cisplatin resistance during chemotherapy is highly related
to cancer mortality and remains a major clinical challenge. Cisplatin is
a cytotoxic compound that causes apoptosis through DNA damage
by the formation of interstrand or intrastrand adducts. The response
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to cisplatin is a complex and multifactorial process that leads to the
activation of several pathways organized in a large network and trans-
mitting proapoptotic or antiapoptotic signals [5,6]. The major mecha-
nisms of resistance that have been identified so far involve reduced drug
uptake, increased drug efflux, increased repair of platinum-DNA ad-
ducts, increased tolerance of DNA damage, and increased levels of
intracellular thiols such as glutathione and metallothionein [5–8].
Although many putative cisplatin resistance mechanisms have been
identified and characterized in vitro, their relevance to clinical resistance
has been difficult to prove. The mechanisms underlying clinical cis-
platin resistance remain poorly understood because no single over-
arching mechanism predominates even within the same histological
subtype of ovarian cancer. A better understanding of the molecular
mechanisms of drug resistance is fundamental to reduce cancer mortal-
ity in ovarian cancer patients.
Annexin A11 is a member of the annexin superfamily of structur-
ally related Ca2+-dependent phospholipid-binding proteins. Despite
their structural similarities, annexins have diverse functions including
cell division, apoptosis, Ca2+ signaling, growth regulation, and secre-
tory function [9–11]. Annexin A11 contains a conserved structural
element, four tandem annexin repeats, in which the Ca2+-binding
sites are located; a unique N-terminal domain rich in glycine, proline,
and tyrosine residues involved in binding to calcyclin (S100A6) and
the apoptosis-linked protein ALG2 [12,13]. Previous studies have
suggested that annexin A11 may play a role in cellular DNA synthesis
and in cell proliferation as well as in membrane trafficking events such
as exocytosis [14–18]. Several members of the annexin superfamily
had been demonstrated to be involved in drug resistance in a variety
of human cancers [19–22]. Different drugs may have different effects
on the expression of certain proteins. Recently, we have shown that
annexin A11 was downregulated in cisplatin-resistant ovarian cancer
cells compared with their parental cells; expressions of annexin A11
were significantly lower in recurrent tumors than those in the primary
ovarian cancers; a lower expression of annexin A11 was significantly
associated with earlier recurrence of ovarian cancers; and annexin
A11 immunoreactivity inversely correlated with in vitro cisplatin resis-
tance in ovarian cancers [23].
To further elucidate the molecular mechanism underlying the
observed association between annexin A11 and cisplatin resistance
in ovarian cancer, we carried out the functional study using small
interfering RNA (siRNA) followed by various in vitro assays. To
identify potential downstream annexin A11–associated targets, a
comprehensive time course study of cisplatin response in ovarian
cancer cells with/without suppression of annexin A11 expression
using whole-genome oligonucleotide microarrays was performed in
this study.
Materials and Methods
Cell Lines and Culture
Two cisplatin-sensitive ovarian cancer cell lines, 2008 and HEY,
which were kindly provided by Dr. S.B. Howell, were used in this study
[23]. All parental cell lines were maintained in drug-free RPMI-1640
medium (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (Hyclone, Logan, UT) and 1%
penicillin-streptomycin (Invitrogen) at 37°C in a humidified atmo-
sphere containing 5% CO2. All transfected cell lines were cultured in
the same growth medium without antibiotics.
siRNA Knockdown of Annexin A11 Gene Expression
All stealth RNA interference (RNAi) sequences were purchased from
Invitrogen. The three stealth RNAi that targeted different annexin
A11 sequences were as follows: A1, GGCCGUGGUGAAAUGUCU-
CAAGAAU; A2, CCUCCUGGACAUCAGAUCAGAGUAU; and
A3, GGGAUUACCGGAAGAUUCUGCUGAA. The stealth RNAi-
negative control duplex (medium GC) was used as a negative control.
Transfection of annexin A11-specific siRNA and the negative control
was performed using Lipofectamine 2000 (Invitrogen). The optimized
dose and duration of RNAi silencing were experimentally determined.
Briefly, cancer cells were seeded the day before siRNA transfection in
either six-well plates or T25 flasks and were 30% to 50% confluent at
the time of transfection. Stealth RNAi and Lipofectamine were diluted
in Opti-MEM I Medium (Invitrogen), and 40 nM of the siRNA
duplex was used in each transfection mixture. 2008 or HEY cells were
transfected with one annexin A11–specific siRNA (A1 or A2 or A3) or
a combination of three different siRNA at the equal amount (A1-3)
or negative control for 2 to 3 days and were then harvested for the
downstream experiments.
Cell Proliferation Assay
Cell Counting Kit-8 (CCK-8; Dojindo, Gaithersburg, MD) was
used in cell proliferation assay. Briefly, 2008 and HEY cells were cul-
tured in T25 flasks and transfected with annexin A11–specific siRNA
(A1) or negative control for 3 days. Cells were then collected by tryp-
sinization, counted by using a hemacytometer with trypan blue dye,
and plated at 3000 viable cells per well into 96-well tissue culture
plates in a final volume of 100 μl. Every 24 hours, a plate was sub-
jected to assay by adding 10 μl of CCK-8 solution to each well,
and the plate was further incubated for 4 hours at 37°C. The absor-
bance at 450 nm was measured with a microplate reader (EL 312e;
Biotek Instruments, Winooski, VT). The experiment was performed
in eight replicates.
Cell Colony Formation Assay
2008 and HEY cells were cultured in T25 flasks and transfected
with A1 or negative control for 3 days. Cells were then collected,
counted, and plated at 3000 viable cells per well into six-well plates.
Six days after plating, cells were fixed with methanol and stained with
0.1% crystal violet, and colonies were counted under the light micro-
scope. The experiment was performed in six replicates.
Cell Cytotoxicity Assay
2008 cells were cultured in T25 flasks and transfected with A1 or
negative control for 3 days. Cells were then collected, counted, and
plated at 3000 viable cells per well into 96-well plates in a final volume
of 100 μl. After incubating overnight, cells were treated with various
concentrations of cisplatin diluted in 100 μl of conditioned medium
(the final concentrations of cisplatin were 0, 1.56, 3.13, 6.25, 12.5,
25, 50, and 100 μg/ml). After incubating for 72 hours, the plates
were assayed by CCK-8 as above. The experiment was performed in
four replicates.
Time Course Experiment of Annexin A11–Associated
Cisplatin Response and Sample Preparations
2008 cells were cultured in T150 flasks and transfected with A1 or
negative control for 2 days. Cells were then collected, counted, and
placed into 100-mm dishes. After incubating overnight, transfected
cells were at 50% confluence and treated with 10 μM cisplatin
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(Sigma-Aldrich, St. Louis, MO) for 0, 8, 16, and 24 hours and then
harvested in two portions for both total RNA and total protein extrac-
tions at every single time point. The optimized dose and duration of
cisplatin treatment were experimentally determined in a previous study
[23]. Total RNA was isolated using TRIZOL reagent (Invitrogen) fol-
lowed by RNeasy mini kit with DNase on-column digestion (Qiagen,
Valencia, CA). RNA was quantified with NanoDrop ND-1000 fol-
lowed by quality assessment with the 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA) according to manufacturer’s protocol.
Agilent Whole-Genome Oligo Microarray
Total RNA was labeled using Agilent Low RNA Input Fluorescent
Linear Amplification Kit (Agilent) following the manufacturer’s instruc-
tion with minor modifications. Briefly, 0.4 μg of RNA was reverse-
transcribed into cDNA byMMLV-RTusing an oligo dT primer (System
Biosciences, Mountain View, CA) that incorporated a T7 promoter
sequence. The cDNA was then used as a template for in vitro transcrip-
tion in the presence of T7 RNA polymerase and cyanine-3–labeled
CTPs (Perkin Elmer Life Sciences, Boston, MA). RNA spike-in con-
trols (Agilent) were added to RNA samples before amplification and
labeling. The labeled cRNA was purified using the RNeasy mini kit
(Qiagen). A total of 0.825 μg of each Cy3-labeled sample was used for
hybridization on Agilent 4× 44K whole human genome microarray at
65°C for 17 hours in a hybridization oven with rotation. After hybridiza-
tion, slides were washed and dried using stabilization and drying solu-
tion according to the Agilent microarray processing protocol. Slides
were scanned using the AgilentMicroarray Scanner controlled by Agilent
Scan Control 7.0 software.
Microarray Data Analysis
Microarray data were extracted with Agilent Feature Extraction
9.5.3.1 software and imported into GeneSpring GX 10 (Agilent).
Normalization was done with all intensities higher than 5 by cross-
array quantile normalization in log2 scale. Data were then trans-
formed back to original scale for the remaining analysis. Features
with intensities smaller than 300 at all time points were excluded
from the analysis, and the resulting data were used for principal com-
ponent analysis using MATLAB version 7.5 software. To identify
genes that were differentially expressed at different time points, genes
that were either upregulated or downregulated more than two-fold
at 8, 16, or 24 hours compared with 0 hour in both cell lines after
cisplatin exposure were selected. To identify genes that were differ-
entially expressed between transfected cells with or without annexin
A11 silencing, genes with a fold up-regulation or down-regulation of
at least two at every single time point were chosen. The identified genes
were then clustered and the heat maps representing gene expression
at different time points were generated using the Cluster and TreeView
software. Gene ontology analysis was performed using the Ingenuity
pathway analysis program.
Real-time Reverse Transcription–Polymerase Chain Reaction
Total RNA was isolated from the different cancer cell lines using
TRIZOL (Invitrogen) according to the manufacturer’s instructions.
One microgram of total RNA was used to generate cDNA using the
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). One microliter
of the resulting cDNA was used in the subsequent polymerase chain
reaction (PCR) in iQ SYBR Green Supermix (Bio-Rad), with the fol-
lowing cycles: 95°C for 3 minutes followed by 50 cycles at 95°C for
30 seconds, at 60°C for 30 seconds, and at 72°C for 55 seconds. An
experiment consisted of triplicate amplification reactions for each gene
product being analyzed. The GAPDH mRNA was used as an internal
control for equal sampling of total RNA from one cell to another. The
cycle threshold number (CT) was determined for each PCR using
iQ5 Real-time PCR Detection System (Bio-Rad). The comparative
CT method was used to calculate the relative abundance of a target
transcript with regard to an internal control (GAPDH ). Results are
expressed as relative abundance of a specific mRNA between control
and experimental sample (fold change, mean ± SD). Sequences and
product sizes for all of genes are shown in Table W1.
Immunoblot Analysis
The denatured samples were electrophoresed on 4% to 15% gra-
dient SDS-PAGE gels (Bio-Rad), electroblotted on nitrocellulose
membranes (Bio-Rad), and probed with the respective antibodies
against different targets. Both anti–annexin A11 (1:10,000) and anti–
annexin A5 (1:2000) monoclonal antibodies were purchased from BD
Biosciences (San Jose, CA). Rabbit anti–human HMOX1 polyclonal
antibody (1:500) and mouse polyclonal anti-LY6D (1:500) were pur-
chased from GenWay Biotech (San Diego, CA) and Novus Biologicals
(Littleton, CO), respectively. The bound antibodies were visualized
with horseradish peroxidase–conjugated secondary antibodies and
enhanced chemiluminescence (Amersham, Pittsburgh, PA). Actin in
the corresponding cell lysates was used as an additional control to show
equal loading.
Tissue Microarrays and Immunohistochemistry
In accordance with the human subject research guidelines of in-
stitutional review board, formalin-fixed, paraffin-embedded tissues
were obtained from the Department of Pathology at Johns Hopkins
Hospital. These included 150 ovarian carcinoma tissues, which are
90 primary tumors, 52 first recurrent tumors, and 8 second or third
recurrent tumors. Detailed clinicopathologic characteristics of the
study cohort have been previously described [23]. All patients under-
went primary debulking surgery followed by platinum/paclitaxel–
based combined chemotherapy. Tissue microarrays were constructed
to facilitate immunohistochemistry (IHC) using EnVision + System-
HRP kit (Dako, Carpinteria, CA) with an anti–annexin A11 mono-
clonal antibody (1:200; BD Biosciences) [23] and an anti–HMOX1
polyclonal antibody (1:200; BioVision, Mountain View, CA). The
IHC staining of the protein were scored semiquantitatively as described
previously [23]. In vitro cisplatin responses of tumors were assessed by
the extreme drug resistance (EDR) assay (Oncotech, Tustin, CA) and
have been previously described [23].
Statistical Analysis
All of the statistical analyses were performed using the Statistica
6.1 (Statsoft, Tulsa, OK). Data were subjected to Student’s unpaired
t test or Fisher’s exact test. Differences with P < .05 were considered
statistically significant.
Results
Effect and Duration of Silencing of Annexin A11
Using siRNA
As shown in Figure 1, A and B, after 3 days of siRNA transfection
at the concentration of 40 nM, annexin A11–specific siRNA, either
applied individually (A1, A2, and A3) or in combination (A1-3), sig-
nificantly decreased annexin A11 mRNA and protein expression levels
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in 2008 cells. Quantitative real-time PCR revealed that there were
about three-fold to four-fold of down-regulation in annexin A11
mRNA expression levels in RNAi-treated cells (A1, A2, A3, and
A1-3) compared with negative control cells (−Ctr, P < .05). Immuno-
blot analysis showed that there were only barely detectable annexin
A11 protein expressions in RNAi-treated cells (A1, A2, A3, and
A1-3) compared with annexin A11 strong expressions in negative con-
trol cells (−Ctr) and parental cells without treatment (Wt). Immuno-
blot analysis revealed a dose-dependent silencing effect of annexin A11
expression in RNAi (A1)-treated 2008 cells at the concentrations rang-
ing from 5 to 40 nM (Figure 1C). In addition, our experimental data
demonstrated that the effect of silencing of annexin A11 protein ex-
pressions in 2008 and HEY cells lasted at least for 10 or 7 days after
3 or 2 days of siRNA transfection at the concentration of 40 nM, re-
spectively (Figure 1D).
Knockdown of Annexin A11 Reduced Cancer Cell
Proliferation and Colony Formation Ability
Cell growth and apoptosis are intimately related [24–28]. To de-
termine the effect of annexin A11 on cell growth of ovarian cancer,
we performed cell proliferation assay and cell colony formation assay
after RNAi silencing of annexin A11 expression in 2008 and HEY
cells. We observed a significantly (P < .05) slower rate of proliferation
(40% or 34% decreased) of the annexin A11–specific siRNA trans-
fectants compared with that of the negative control transfectants in
both 2008 and HEY cells (Figure 2, A and B). Suppression of annexin
A11 expression also greatly damaged 2008 cell colony formation abil-
ities (P < .01; Figure 2C). HEY cells did not form countable colonies
during their growth process. These data suggested that annexin A11
plays an important role in cell proliferation of ovarian cancer.
Epigenetic Silencing of Annexin A11 Conferred
Chemoresistance to Ovarian Cancer Cells
Previously, we reported that annexin A11 is associated with cisplatin
resistance and related to tumor recurrence in ovarian cancer patients
[23]. To directly demonstrate the involvement of annexin A11 in cis-
platin resistance of ovarian cancer cells, the cisplatin-sensitive 2008
cells were transfected with an annexin A11–specific siRNA or negative
control followed by cell cytotoxicity assay. The sensitivities of the pair
of cell lines to the cytotoxic effect of cisplatin were determined. Dose-
response curves were plotted on a semilog scale as the percentage of the
control cell number, which was obtained from the sample without
Figure 1. Knockdown of annexin A11 expression in ovarian cancer cells. (A and B) Effect of silencing of annexin A11 using different siRNA.
2008 cells were treated with one (A1 or A2 or A3) or a combination (A1-3) of three stealth RNA against annexin A11 or nonspecific sequence
(−Ctr) at the concentration of 40 nM or without treatment (Wt) for 3 days. Immunoblot analysis (A) and real-time PCR (B) were performed
to confirm the suppression of annexin A11 mRNA and protein expressions in the cells. β-Actin was taken as an additional control for equal
sampling in immunoblot analysis (A). The relative mRNA expression level of each sample was normalized to GAPDH expression and com-
pared with −Ctr sample. *P < .05 (B). (C) Dose-dependent silencing of annexin A11 by siRNA. 2008 cells were treated with RNAi (A1)
at the indicated concentrations of 40, 20, 10, or 5 nM or −Ctr at the concentration of 40 nM or without treatment (Wt) for 3 days. Immuno-
blot analysis (C) was performed to check the annexin A11 expression levels in the cells. β-Actin was taken as an additional control for equal
sampling. (D) Duration of silencing of annexin A11 using siRNA. 2008 or HEY cells were treated with RNAi (A1) or −Ctr at the concentra-
tion of 40 nM. Immunoblot analysis was performed to analyze the annexin A11 expression levels in these cells. Note that the level of annexin
A11 protein was significantly decreased by day 3 (2008; left top), day 10 (2008; left bottom), day 2 (HEY; right top), or day 7 (HEY; right
bottom), respectively. β-Actin or annexin A5 was taken as a loading control or off-target effect control.
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drug exposure. The experimental data showed that epigenetic silencing
of annexin A11 expression significantly enhanced cisplatin resistance
in 2008 cells (P < .01; Figure 2D). IC50 in two cell lines are 42 and
16 μM, respectively, with a 2.6-fold increase in RNAi cells compared
with control cells. These data are consistent with the previous observa-
tion of an association between annexin A11 and cisplatin resistance in
ovarian cancer [23].
Dynamic Response of Gene Expression to Cisplatin
Treatment and Annexin A11–Associated Gene
Expression Alterations
To better understand the molecular mechanisms through which
annexin A11 plays an important role in cell proliferation and drug re-
sistance of ovarian cancer and to identify potential downstream annexin
A11–associated targets, we performed time course profiling of gene ex-
pressions of both annexin A11–specific siRNA (R group) and negative
control (N group) transfected ovarian cancer cells treated with cisplatin
for different durations using the Agilent 44K whole genome oligo
microarrays. Unsupervised analysis using principal component analysis
indicated that cisplatin treatment has a major effect on global gene ex-
pression patterns of both cell lines at all time points (data not shown).
During the time course of cisplatin exposure, a total of 6 genes were
either upregulated or downregulated at 8 hours after treatment with
cisplatin, 19 after 16 hours and 47 after 24 hours in both groups of
cells (Figure 3, A–C). Most genes that altered at 8 hours (5/6) main-
tained their alterations of gene expression at 16 and/or 24 hours,
representing a set of genes that were earlier and lasting responders to
cisplatin exposure (Figure 3A). H1F0, MB2, DERP12, and ZA31P
showed consistent alterations (either up-regulation or down-regulation)
of gene expression at all time points in both groups of cells. By 16 hours
of cisplatin exposure, another major pattern of gene expression began
to emerge. There were 15 genes that were altered at 16 hours but not
at 8 hours and maintained their alterations at 24 hours. Among them,
12 genes including MX1, KRT6C, ISGF3G, IFI44, IFIT1, IFI44L,
ADAMTS1, pTR7, DHRS2, IL8, CXCL2, and IL1R2 showed consis-
tent down-regulations of gene expression at 16 and 24 hours in both
groups of cells, which were organized into a major cluster (Figure 3B).
SERPINB2 was increased at 8 hours but decreased at 16 and 24 hours
in both groups of cells, whereas PCSK9 was decreased at 8 hours but
increased at 16 and 24 hours in both groups of cells. By 24 hours, more
genes were included into this major cluster of downregulated genes,
and a new major cluster of upregulated genes including PCSK9 was
also formed as shown in Figure 3C , suggesting the establishment of a
large gene expression program in response to cisplatin exposure. Inter-
estingly, among these genes, both PLEKHM1 and A_24_P932355
showed total different responses to cisplatin treatment in both groups
of cells. They were decreased in R group cells at 8, 16, and 24 hours,
whereas they increased in N group cells at 8, 16, and 24 hours. The
Figure 2. Epigenetic silencing of annexin A11 reduces cell proliferation, colony formation ability, and confers cisplatin resistance to ovarian
cancer cells. (A and B) Cell proliferation assay. 2008 (A) or HEY (B) cells were treated with RNAi (A1) or −Ctr at the concentration of 40 nM
for 3 days, respectively, and then plated at 3000 viable cells per well into 96-well plates. Every 24 hours, one plate was subjected to assay
by CCK-8 kit. The data in each time point are averaged values from eight replicates (P < .05). (C) Colony formation assay. 2008 cells were
treated in same way as above for 3 days and then plated at 3000 viable cells per well into six-well plates. Six days after plating, cells were
fixed with methanol and stained with 0.1% crystal violet and colonies were counted. The experiment was performed in six replicates (P <
.01). (D) Cell cytotoxicity assay. 2008 cells were treated in same way as above for 3 days and then plated at 3000 viable cells per well into
96-well plates. After incubating overnight, cells were treated with various concentration of cisplatin diluted in 100 μl of conditioned medium
(the final concentrations of cisplatin were 0, 1.56, 3.13, 6.25, 12.5, 25, 50, and 100 μg/ml). After continuous incubation for 72 hours, the
plates were subjected to assay by CCK-8 kit. The experiment was performed in three replicates (P < .01). Three independent experiments
were performed for each assay.
Neoplasia Vol. 11, No. 6, 2009 Suppression of Annexin A11 Confers Chemoresistance Song et al. 609
above identified genes altered during the time course of cisplatin expo-
sure include some genes involved in apoptosis (PCSK9, SERPINB2,
MX1), cell cycle/cell proliferation (H1F0, IL8, ADAMTS1, ATP8A2,
DHRS2, KRT6C), signal transduction (IL8, ZCCHC2, ARF3, JAK3,
KCNMB4, NGEF, PLEKHM1, TNC, CXCL2, GNAZ, GPR30, MX1,
SOST ), transcription regulation (L3MBTL, ZNF358, ISGF3G), cell
adhesion (IL8,TNC ), cell motility/migration (IL8, S100P),metabolism
(DHRS2, PCSK9, METTL7A, UBE2E1), immune response (IL8,
CXCL2, IL1R2, IFIT1, ISGF3G, MX1, MX2), and nucleotide bind-
ing (ARF3, ATP8A2, GNAZ, H1F0, HSPA2, JAK3, MX1, MX2,
NAV3, ZCCHC2, ZAF358).
A total of 26 genes were identified as annexin A11–associated
genes (Figure 3D). Their expression levels were either increased (n =
21) or decreased (n = 5) after silencing of annexin A11. In this study,
only genes with a fold up-regulation or down-regulation of at least 2 at
every single time point were selected for validation. Table 1 lists these
genes with averaged fold changes over all the time points, which were
ordered accordingly. The identified annexin A11–associated genes in-
clude some genes involved in apoptosis/cell proliferation (HMOX1,
MX1, GLI1, TGFBI, IFITM1, EIF4EBP2, HTRA3, IFI6, KRT4 ),
DNA binding (HMOX1, MX1, HIST1H2BM, HIST1H2BK ), signal
transduction (HMOX1, GLI1, CXCR7, EIF4EBP2, IFITM1), tran-
scription regulation (HMOX1, GLI1, SCML1), cell adhesion (TGFBI,
CDH16, LY6D, PDZD2), and immune response (IFI27, IFI6, ISG15,
MX1). Other genes were either only one gene in one category or with-
out available annotation of gene ontology.
The design of the time course gene expressions profiling study did
not include replicates to allow for proper estimate of false discovery rate
for results in Figure 3, A–C . However, for the results in Figure 3D, the
identification of annexin A11–associated genes, using sample label per-
mutation, the average number of genes with at least two-fold changes
at every single time point was 5.8, indicating an estimated potential
false discovery rate of 22%.
Validation of DNA Microarray Data Using Real-time PCR
Before further effort to unravel the molecular pathways through
which annexin A11 is involved in cell proliferation and drug resistance
of ovarian cancer, the DNA microarray profiling data need to be vali-
dated using alternative platform. We performed real-time PCR assays
to independently determine mRNA expression levels on a set of genes
that were representative of the above gene ontology classes: HMOX1,
PCSK9, and EIF4EBP2 for apoptosis; HMOX1, TGFBI, DHRS2, and
EIF4EBP2 for cell proliferation; TGFBI and LY6D for cell adhesion;
HMOX1 for transcription regulation; HMOX1 and EIF4EBP2 for
Figure 3. Dynamic response of gene expression to cisplatin treatment and annexin A11–associated gene expression alterations. (A–C)
Hierarchical clustering of gene expression alterations. Hierarchical clustering of genes either upregulated or downregulated more than
two-fold change at 8 (A), 16 (B), and 24 hours (C) compared with 0 hour in both RNAi (R groups) and control (N groups) cell lines are
shown. (D) Hierarchical clustering of genes with a fold up-regulation or down-regulation of at least two (R vs N) at every single time point
are also shown. R1-R4 or N1-N4 represents different time points at 0, 8, 16, or 24 hours in order, respectively, in R or N groups. Clustering
was performed using the Cluster and TreeView software. Genes that were increased are shown in red, whereas genes that were decreased
are indicated in blue.
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signal transduction; DHRS2 and PCSK9 for metabolism; HMOX1 for
DNA binding; and S100P for cell migration. As shown in Figure 4A
and Table W2, the consistent up-regulation (HMOX1, TGFBI,
LY6D, and S100P) and down-regulation (EIF4EBP2) of genes sub-
jected to epigenetic silencing of annexin A11 (ANXA11) across all time
points were well validated using real-time PCR. The down-regulation
of DHRS2 that was one representative of the major cluster emerged at
16 and 24 hours after cisplatin exposure was verified in both groups of
cells. PCSK9 that was identified as one of the major clusters of genes
upregulated at the later time point(s) was also investigated using real-
time PCR. Our results showed dynamic responsive patterns of gene
expression that were extremely similar to the microarray data, which
was decreased at 8 hours but increased at 16 and 24hours in both groups
of cells. Overall, the real-time PCR results agreed well with the micro-
array data and confirmed that epigenetic silencing of annexin A11 in
ovarian cancer cells followed by cisplatin exposure led to significant
changes in the expression of genes involved in apoptosis, cell cycling/
proliferation, cell adhesion, cell migration, transcription regulation,
and signal transduction.
Suppression of Annexin A11 Upregulated HMOX1 and
LY6D Protein Expressions
According to our DNA microarray results, HMOX1 and LY6D
were consistently increased by approximately 5.13- or 4.08-fold, respec-
tively, in cells subjected to epigenetic silencing of annexin A11 across
all time points. Using immunoblot analysis, the suppressions of annexin
A11 protein expressions in the R group cells compared with those in
the N group cells were confirmed. Immunoblot analysis showed that
suppression of annexin A11 also upregulated HMOX1 and LY6D pro-
tein expression levels in R1, R2, R3, and R4 compared with N1, N2,
N3, and N4, respectively (Figure 4B).
Annexin A11 Immunointensity Inversely Correlated with
HMOX1 Immunoreactivity in Ovarian Cancer Patients
Owing to the extensive involvement of HMOX1 in different cellular
processes including cell proliferation and apoptosis, we further evalu-
ated the correlation of protein expressions between annexin A11 and
HMOX1 in 150 ovarian carcinoma tissues with IHC staining.HMOX1
immunoreactivity was observed in the cytoplasm of tumor cells (Fig-
ure 4C) and significantly inversely correlated with annexin A11 immuno-
intensity in 142 primary and first recurrent ovarian cancer patients (P =
.04; Figure 4C and Table 2). This inverse correlation exists even more
significantly in 52 first recurrent tumors (P = .01; Table 2). In addi-
tion, among 81 tumors for which the EDR results were available for
analysis, HMOX1 immunoreactivity significantly positively correlated
with in vitro cisplatin resistance (P = .04; Figure 4C). More specifically,
there were approximately 60.6% of ovarian carcinomas with extreme and
intermediate cisplatin resistance exhibited positive HMOX1 immuno-
reactivity, whereas only 37.5% of tumors with low cisplatin resistance
showed positive HMOX1 immunoreactivity.
Discussion
In this study, we demonstrated that annexin A11 was directly in-
volved in cell proliferation and cisplatin resistance of ovarian cancer.
Specifically, using RNAi techniques, we showed that knockdown of
annexin A11 expression reduced cell proliferation and colony for-
mation ability of ovarian cancer cells. Furthermore, we showed that
epigenetic silencing of annexin A11 conferred cisplatin resistance to
ovarian cancer cells. We have previously shown that decreased expres-
sion of annexin A11 was characteristic for cisplatin-resistant ovarian
cancer cells and may contribute to tumor recurrence in ovarian
cancer patients [23]. The experimental results in this study are in
agreement with our previous observation and further underscored
Table 1. Genes Altered upon Expression of Annexin A11.
Gene Symbol Accession No. Description Fold Change
Up-regulation
HMOX1 NM_002133 Heme oxygenase (decycling) 1 +5.13
CDH16 NM_004062 Cadherin 16, KSP-cadherin +4.24
MX1 NM_002462 Myxovirus (influenza virus) resistance 1 +4.14
LY6D NM_003695 Lymphocyte antigen 6 complex, locus D +4.08
IFI27 NM_005532 Interferon, α-inducible protein 27 +4.05
GLI1 NM_005269 Glioma-associated oncogene homolog 1 (zinc finger protein) +3.87
IFITM1 NM_003641 Interferon-induced transmembrane protein 1 (9-27) +3.72
ISG15 NM_005101 ISG15 ubiquitin-like modifier +3.62
LOC730999 XM_001131389 Hypothetical protein LOC730999 +3.30
LOXL4 NM_032211 Lysyl oxidase-like 4 +3.28
PSCA NM_005672 Prostate stem cell antigen +3.24
TGFBI NM_000358 Transforming growth factor, β-induced, 68 kDa +3.19
IFI44L NM_006820 Interferon-induced protein 44-like +2.98
S100P NM_005980 S100 calcium binding protein P +2.90
HTRA3 NM_053044 HtrA serine peptidase 3 +2.73
CXCR7 NM_020311 Chemokine (C-X-C motif ) receptor 7 +2.56
OLFML2A NM_182487 Olfactomedin-like 2A +2.52
IFI6 NM_022873 Interferon, α-inducible protein 6 +2.48
KRT4 NM_002272 Keratin 4 +2.43
PRSS23 NM_007173 Protease, serine, 23 +2.36
PDZD2 NM_178140 PDZ domain containing 2 +2.36
Down-regulation
HIST1H2BM NM_003521 Histone cluster 1, H2bm −2.21
LOC391566 XR_018583 Similar to histone H2B 291B −2.27
EIF4EBP2 NM_004096 Eukaryotic translation initiation factor 4E binding protein 2 −2.30
HIST1H2BK NM_080593 Histone cluster 1, H2bk −2.49
SCML1 NM_006746 Sex comb on midleg-like 1 −2.63
ANXA11 NM_145869 Annexin A11 −3.43
Fold Change (R/N) is the averaged value over all time points.
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the biological relevance of annexin A11 in the drug resistance of
ovarian cancer.
Annexin A11 is a member of the annexin superfamily of Ca2+ and
phospholipid-binding, membrane-associated proteins implicated in
Ca2+ signal transduction processes associated with cell growth and
differentiation [9–11]. Although diverse functions have been ascribed
to annexins, there is no consensus about the role played by the
annexin protein family as a whole [11]. The exact cellular functions
of individual annexin members remain to be determined. Annexin
A11 is ubiquitously expressed in a variety of tissues and cell types
of eukaryotes, but its subcellular distribution varies considerably
[14,17]. The nuclear localization of annexin A11 has been demon-
strated to be cell type–specific and developmentally dependent [14].
Using recombinant human annexin A11–specific autoantibodies
cloned by phage display, annexin A11 was found to be associated with
the mitotic spindles and might play a role in cell division [17]. A com-
bination of confocal and video time-lapse microscopy revealed that
annexin A11 was required for midbody formation and completion
of the terminal phase of cytokinesis [29]. A recent genome-wide asso-
ciation study identified ANXA11 as a new susceptibility locus for sar-
coidosis and surmised that a depletion or dysfunction of annexin A11
may affect the apoptosis pathway in individuals with sarcoidosis and
hence destroy the balance between apoptosis and survival of activated
inflammatory cells [30]. In consistent with these observations, in this
study, knockdown of annexin A11 expression resulted in a slower rate
Figure 4. Validation of DNA microarray data and immunohistochemical analysis. (A) Validation of DNA microarray data by real-time PCR.
The up-regulation (HMOX1, TGFBI, LY6D, and S100P) and down-regulation (EIF4EBP2) of genes associated with annexin A11 expression
(ANXA11) and the dynamic response of gene expression to cisplatin treatment (DHRS2 and PCSK9) were validated using real-time PCR. N
represents control cells and R represents RNAi cells. For each individual gene, the expression levels at different time points were normal-
ized to the control sample (N, PCR, 0 h). In addition, the relative mRNA expression levels were normalized to GAPDH expression. Each
gene was amplified in triplicate, and each experiment was performed three times. *P < .05, R versus N. **P < .05, either [R2 (or R3 or
R4) vs R1] or [N2 (or N3 or N4) vs N1]. (B) Suppression of annexin A11 upregulated HMOX1 and LY6D protein expressions. Immunoblot
analysis was performed to confirm the suppression of annexin A11 protein expressions in the cells. The up-regulations of HMOX1 and
LY6D protein expression levels in R1, R2, R3, and R4 compared with N1, N2, N3, and N4 were demonstrated. β-Actin was taken as an
additional control for equal sampling in immunoblot analysis. (C) Annexin A11 immunointensity inversely correlated with HMOX1 immuno-
reactivity in ovarian cancer patients. Two representative pairs of tissue sections (left two sections from a primary tumor with low EDR and
right two sections from a first recurrent tumor with extreme EDR) stained with two different antibodies are shown. Both sections of each
pair were from similar areas of the same specimen. Original magnifications: upper panel, ×100; lower panel, ×400.
Table 2. Annexin A11 Immunointensity Correlates Inversely with HMOX1 Immunoreactivity in
Ovarian Cancer Patients.
HMOX1 ANXA11 Total
Negative Weak Moderate Strong
Negative 5 (41.7%) 19 (30.2%) 23 (59%) 13 (46.4%) 60
Positive 7 (58.3%) 44 (69.8%) 16 (41%) 15 (53.6%) 82
Total 12 63 39 28 142 (P = .04)
Negative 4 (50%) 5 (16.7%) 6 (66.7%) 3 (60%) 18
Positive 4 (50%) 25 (83.3%) 3 (33.3%) 2 (40%) 34
Total 8 30 9 5 52 (P = .01)
There is an inverse correlation of protein expressions between annexin A11 and HMOX1 in 142 pri-
mary and first recurrent ovarian cancer patients (P = .04). This inverse correlation exists even more
significantly in 52 first recurrent tumors (P = .01).
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of cell growth in two ovarian cancer cell lines, 2008 andHEY, providing
the first evidence that annexin A11 plays an important role in cell pro-
liferation of ovarian cancer. In addition to the classic mechanisms, there
are also several new molecular factors that have been linked to chemo-
resistance such as altered cell signaling pathways or presence of quiescent
noncycling cells [22]. The cell cycle and apoptosis are intimately related,
as evidenced by the central role of p53, both in cell cycle arrest and in the
induction of apoptosis [25]. Conversely, this intimate relation was also
demonstrated both in vitro and clinically; tumor cells that undergo a
growth arrest or have a lower proliferation activity may be protected
from apoptosis andmay therefore be ultimately resistant to the cytotoxic
agent [24,26]. Our results demonstrated that epigenetic silencing of
annexin A11 expression reduced cell proliferation and conferred cis-
platin resistance to ovarian cancer cells, suggesting the possibility that
the observed association between annexin A11 and cisplatin resistance
may be mediated through alterations in cell cycling/proliferation. The
exact mechanism underlying this phenomenon and whether it is uni-
versal or tumor cell type–specific remains to be further investigated.
Although cancer cells with intrinsic or acquired cisplatin resistance
have been extensively analyzed to identify genomic or proteomicmarkers
involved in drug resistance, the exact timing of transcriptional response
to cisplatin treatment remains unclear. This longitudinal analysis of both
annexin A11–specific siRNA and negative control–transfected ovarian
cancer cells for their response to cisplatin treatment allowed us to iden-
tify some patterns of gene expressions in response to cisplatin exposure.
A set of genes altered at 8 hours and maintained their alterations of gene
expression at 16 and 24 hours, representing earlier and lasting re-
sponders to cisplatin exposure. By 16 hours of cisplatin exposure, another
major pattern of gene expression (down-regulation) began to emerge
and maintained their alterations, with more genes included into this
major cluster at 24 hours. Furthermore, the third major pattern of gene
expression (up-regulation) was formed at 24 hours after initial down-
regulations of gene expressions at 8 hours of cisplatin exposure. These
major patterns of gene expression suggested the establishment of a large
gene expression program in response to cisplatin exposure. Many of
these genes have been involved in apoptosis, cell cycle/proliferation,
signal transduction, transcription regulation, cell adhesion, cell motility/
migration, metabolism, and immune response. Tumor cells, in contrast
to normal cells, respond to cisplatin exposure with transient gene ex-
pression to protect or repair their chromosomes. Some genes could serve
as the master switch for turning on other genes in response to DNA-
damaging agents and play a major role in cisplatin resistance. PLEKHM1
was previously reported to be involved in colon cancer cells’ response to
cisplatin exposure [31]. Interestingly, in this study, PLEKHM1 showed
totally different responses to cisplatin treatment in both groups of cells.
In this study, we also identified a set of genes that are differentially
expressed at all time points between two groups of cell lines, which
represents the annexin A11–associated gene expression alterations.Many
of these genes have been involved in apoptosis/cell proliferation, DNA
binding, signal transduction, transcription regulation, and cell adhe-
sion. Among them, the up-regulation of heme oxygenase 1 (HMOX1)
or heat shock protein 32 (HSP32) seems particularly interesting because
this inducible isoform of heme oxygenase has been shown to occur
in various tumor tissues and contribute to tumor progression [32,33].
HMOX1 was reported to modulate different cellular functions includ-
ing cytokine production, cell proliferation, and apoptosis and can exert
unique cytoprotective effects [32–34]. It has previously been shown
that HMOX1 attenuated the cisplatin-induced apoptosis of auditory
cells [34] and that suppression of Nrf2-driven HMOX1 enhanced the
chemosensitivity of lung cancer cells toward cisplatin [33]. In this
study, HMOX1 immunoreactivity inversely correlated with annexin
A11 immunointensity and positively correlated with in vitro cisplatin
resistance in ovarian cancer patients, which suggested that HMOX1
may also collectively serve as a potential marker for ovarian cancer
chemoresistance, and inhibition of intratumoral annexin A11–regulated
HMOX1 activity may be a potential therapeutic strategy in human
ovarian cancers. The extracellularmatrix protein TGFBI inducedmicro-
tubule stabilization and sensitized ovarian cancers to paclitaxel [35].
LY6D was reported to be a chemotherapy-induced antigen and has
been used both as a therapeutic target and as a diagnostic marker for
head and neck cancer [36–38]. S100P sensitizes ovarian cancer cells
to carboplatin and paclitaxel in vitro [39]. IFITM1 was identified as
a potent marker of cis-platinum response in esophageal cancer [40]. In
this study, these annexin A11–associated genes were coordinately regu-
lated to provide relatively different baselines in terms of gene expres-
sion and might be responsible for the observed phenotype changing
of cancer cells.
In conclusion, this study shows that annexin A11 is directly in-
volved in cell proliferation and cisplatin resistance of ovarian cancer.
Through a time course study of cisplatin response in ovarian cancer
cells with/without suppression of annexin A11 expression, we identi-
fied a set of differentially expressed genes associated with annexin A11
expression and patterns of gene expressions in response to cisplatin
exposure. Many of them such as HMOX1, TGFBI, LY6D, S100P,
EIF4EBP2, DHRS2, and PCSK9 have been involved in apoptosis, cell
cycling/proliferation, cell adhesion/migration, transcription regulation,
and signal transduction. HMOX1 immunoreactivity inversely corre-
lated with annexin A11 immunointensity and positively correlated with
in vitro cisplatin resistance in ovarian cancer patients. Further charac-
terization of these genes may contribute to a better understanding of the
molecular mechanism through which annexin A11 plays an important
role in cell proliferation and drug resistance of ovarian cancer. Manipu-
lation of annexin A11 and its associated genes may represent a novel
therapeutic strategy in human ovarian cancers.
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Table W1. Primer Sequences and Product Size.
Primer Name Sequence Product Size (bp)
ANXA11-F 5′-cggcagcagatcctactttc-3′
ANXA11-R 5′-atcaggcaggcttcatcagt-3′ 185
HMOX1-F 5′-atgacaccaaggaccagagc-3′
HMOX1-R 5′-gtgtaaggacccatcggaga-3′ 153
TGFBI-F 5′-gtgtgtgctgtgcagaaggt-3′
TGFBI-R 5′-ttgagagtggtagggctgct-3′ 172
LY6D-F 5′-cttctgcaagaccacgaaca-3′
LY6D-R 5′-ctcattgcacaggtcctcct-3′ 154
S100P-F 5′-taccaggcttcctgcagagt-3′
S100P-R 5′-ctccagggcatcatttgagt-3′ 177
EIF4EBP2-F 5′-gttggggatgatgctcagtt-3′
EIF4EBP2-R 5′-ctgtaatggggactgctggt-3′ 153
DHRS2-F 5′-gccctacatggagaacagga-3′
DHRS2-R 5′-accaatcctcaccactttgc-3′ 217
PCSK9-F 5′-accctcataggcctggagtt-3′
PCSK9-R 5′-gagtagaggcaggcatcgtc-3′ 188
GAPDH-F 5′-ccagggctgcttttaact-3′
GAPDH-R 5′-ctcgctcctggaagata-3′ 186
Table W2. Validation of DNA Microarray Data Using Real-time PCR.
Gene R1/N1 R2/N2 R3/N3 R4/N4 N2/N1 N3/N1 N4/N1 R2/R1 R3/R1 R4/R1
ANXA11 Chip −3.12 −3.55 −3.56 −3.52 +1.17 +1.12 +1.00 +1.03 −1.02 −1.15
PCR −3.16 −3.81 −3.26 −3.67 −1.05 −1.09 −1 −1.27 −1.13 −1.16
P .0226 .004 .0159 .0139 .4164 .3645 .5 .1776 .3221 .2891
HMOX1 Chip +5.53 +4.64 +4.54 +5.13 +1.17 +1.12 −1.40 −1.02 −1.09 −1.33
PCR +6.28 +6.23 +6.34 +3.06 +1.12 −1.3 −1.09 +1.11 −1.28 −2.24
P .0121 .0041 .0192 .0349 .3403 .1998 .3963 .283 .189 .0265
TGFBI Chip +2.78 +3.04 +3.61 +3.34 −1.29 −1.36 −1.18 −1.18 −1.05 +1.01
PCR +2.6 +3.94 +3.72 +3.8 −1.86 −1.81 −1.54 −1.23 −1.26 −1.05
P .0131 .0045 .0076 .0056 .0285 .0317 .0553 .1355 .142 .3713
LY6D Chip +5.08 +5.20 +3.21 +2.83 −1.26 +1.47 +1.91 −1.23 −1.08 +1.07
PCR +5.31 +5.75 +3.22 +2.7 −1.67 +1.17 +1.57 −1.34 −1.23 −1.09
P .032 .0047 .0089 .0134 .0486 .1927 .0559 .0855 .1472 .3175
S100P Chip +2.35 +2.99 +3.22 +3.03 −1.48 −2.55 −2.09 −1.17 −1.86 −1.62
PCR +3.14 +3.1 +3.02 +2.83 −1.34 −2.24 −2.07 −1.36 −2.33 −2.29
P .016 .0071 .0057 .0235 .1242 .0282 .0286 .0603 .0097 .0157
EIF4EBP2 Chip −2.48 −2.30 −2.17 −2.25 +1.14 +1.01 −1.06 +1.23 +1.16 +1.04
PCR −2.83 −2.17 −1.81 −1.72 +1.01 −1.22 −1.3 +1.31 +1.28 +1.27
P .0041 .0041 .0296 .0318 .4608 .1397 .0836 .0259 .0581 .1135
DHRS2 Chip −1.67 −1.45 −1.03 +1.01 −1.37 −3.52 −5.41 −1.18 −2.17 −3.21
PCR −1.67 −1.34 −1.04 −1.3 −1.58 −5.55 −8.82 −1.27 −3.44 −6.87
P .0735 .0852 .4102 .0773 .0777 .0068 .0089 .1825 .0398 .0103
PCSK9 Chip +1.64 +2.01 +1.22 +1.36 −1.99 +2.79 +3.74 −1.62 +2.07 +3.11
PCR −1.05 +1.36 +1 +1.34 −2.66 +2.17 +2.25 −1.87 +2.28 +3.16
P .3917 .0773 .4919 .0689 .0139 .0223 .0179 .0242 .0118 .0065
P values are shown for the real-time PCR assays. Differences with P < .05 were considered statistically significant (in boldface). P values with underline represent validated gene alterations in both chip
and PCR platforms, but P values without underline represent statistically significant gene alterations only in PCR platform.
